Connect Biopharma Holdings (CNTB) Total Current Liabilities (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Total Current Liabilities for 7 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 99.01% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 99.01% YoY) and the FY2025 annual result came in at $13.6 million, up 60.87% from the prior year.
• Total Current Liabilities grew to $17.0 million in Q1 2026 per CNTB's latest filing, from $13.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for CNTB reached as high as $25.3 million in Q4 2023 and fell as low as $8.5 million in Q4 2024.
• A 5-year average of $14.1 million and a median of $13.6 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities sank 66.54% — and 2026, when it surged 99.01%.
• Year by year, Total Current Liabilities stood at $15.3 million in 2022, then surged by 65.31% to $25.3 million in 2023, then plunged by 66.54% to $8.5 million in 2024, then jumped by 60.87% to $13.6 million in 2025, then gained by 25.21% to $17.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $17.0 million, $13.6 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.